Effectiveness of 2 and 3 mRNA COVID-19 Vaccines Doses against Omicron and Delta-Related Outpatient Illness among Adults, October 2021 – February 2022
Abstract Background We estimated SARS-CoV-2 Delta and Omicron-specific effectiveness of 2 and 3 mRNA COVID-19 vaccine doses in adults against symptomatic illness in US outpatient settings.Methods Between October 1, 2021, and February 12, 2022, research staff consented and enrolled eligible participants who had fever, cough, or loss of taste or smell and sought outpatient medical care or clinical SARS-CoV-2 testing within 10 days of illness onset. Using the test-negative design, we compared the odds of receiving 2 or 3 mRNA COVID-19 vaccine doses among SARS-CoV-2 cases versus controls using logistic regression. Regression models were adjusted for study site, age, onset week, and prior SARS-CoV-2 infection. Vaccine effectiveness (VE) was calculated as (1 – adjusted odds ratio) x 100%.Results Among 3847 participants included for analysis, 574 (32%) of 1775 tested positive for SARS-CoV-2 during the Delta predominant period and 1006 (56%) of 1794 participants tested positive during the Omicron predominant period. When Delta predominated, VE against symptomatic illness in outpatient settings was 63% (95% CI: 51% to 72%) among mRNA 2-dose recipients and 96% (95% CI: 93% to 98%) for 3-dose recipients. When Omicron predominated, VE was 21% (95% CI: -6% to 41%) among 2-dose recipients and 62% (95% CI: 48% to 72%) among 3-dose recipients.Conclusions In this adult population, 3 mRNA COVID-19 vaccine doses provided substantial protection against symptomatic illness in outpatient settings when the Omicron variant became the predominant cause of COVID-19 in the U.S. These findings support the recommendation for a 3rdmRNA COVID-19 vaccine dose..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Sara S. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.04.06.22273535 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI035726067 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI035726067 | ||
| 003 | DE-627 | ||
| 005 | 20240425104510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.04.06.22273535 |2 doi | |
| 035 | |a (DE-627)XBI035726067 | ||
| 035 | |a (biorXiv)10.1101/2022.04.06.22273535 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Sara S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of 2 and 3 mRNA COVID-19 Vaccines Doses against Omicron and Delta-Related Outpatient Illness among Adults, October 2021 – February 2022 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background We estimated SARS-CoV-2 Delta and Omicron-specific effectiveness of 2 and 3 mRNA COVID-19 vaccine doses in adults against symptomatic illness in US outpatient settings.Methods Between October 1, 2021, and February 12, 2022, research staff consented and enrolled eligible participants who had fever, cough, or loss of taste or smell and sought outpatient medical care or clinical SARS-CoV-2 testing within 10 days of illness onset. Using the test-negative design, we compared the odds of receiving 2 or 3 mRNA COVID-19 vaccine doses among SARS-CoV-2 cases versus controls using logistic regression. Regression models were adjusted for study site, age, onset week, and prior SARS-CoV-2 infection. Vaccine effectiveness (VE) was calculated as (1 – adjusted odds ratio) x 100%.Results Among 3847 participants included for analysis, 574 (32%) of 1775 tested positive for SARS-CoV-2 during the Delta predominant period and 1006 (56%) of 1794 participants tested positive during the Omicron predominant period. When Delta predominated, VE against symptomatic illness in outpatient settings was 63% (95% CI: 51% to 72%) among mRNA 2-dose recipients and 96% (95% CI: 93% to 98%) for 3-dose recipients. When Omicron predominated, VE was 21% (95% CI: -6% to 41%) among 2-dose recipients and 62% (95% CI: 48% to 72%) among 3-dose recipients.Conclusions In this adult population, 3 mRNA COVID-19 vaccine doses provided substantial protection against symptomatic illness in outpatient settings when the Omicron variant became the predominant cause of COVID-19 in the U.S. These findings support the recommendation for a 3rdmRNA COVID-19 vaccine dose. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Chung, Jessie R. |e verfasserin |0 (orcid)0000-0001-5205-966X |4 aut | |
| 700 | 1 | |a Talbot, H. Keipp |e verfasserin |4 aut | |
| 700 | 1 | |a Grijalva, Carlos G. |e verfasserin |4 aut | |
| 700 | 1 | |a Wernli, Karen J. |e verfasserin |4 aut | |
| 700 | 1 | |a Kiniry, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Emily T. |e verfasserin |4 aut | |
| 700 | 1 | |a Monto, Arnold S. |e verfasserin |4 aut | |
| 700 | 1 | |a Belongia, Edward A. |e verfasserin |4 aut | |
| 700 | 1 | |a McLean, Huong Q. |e verfasserin |0 (orcid)0000-0003-2725-6439 |4 aut | |
| 700 | 1 | |a Gaglani, Manjusha |e verfasserin |4 aut | |
| 700 | 1 | |a Mamawala, Mufaddal |e verfasserin |4 aut | |
| 700 | 1 | |a Nowalk, Mary Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Geffel, Krissy Moehling |e verfasserin |4 aut | |
| 700 | 1 | |a Tartof, Sara Y. |e verfasserin |4 aut | |
| 700 | 1 | |a Florea, Ana |e verfasserin |0 (orcid)0000-0003-0030-8737 |4 aut | |
| 700 | 1 | |a Lee, Justin S. |e verfasserin |4 aut | |
| 700 | 1 | |a Tenforde, Mark W. |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Manish M. |e verfasserin |4 aut | |
| 700 | 1 | |a Flannery, Brendan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1111/irv.13029 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.04.06.22273535 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||